Brownstein Carrie 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Oct 3, 2022
Insider Transaction Report
Form 4
Brownstein Carrie
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-10-03+300,000→ 300,000 totalExercise: $22.21Exp: 2032-10-02→ Common Stock (300,000 underlying) - Award
Common Stock
2022-10-03+100,000→ 100,000 total - Award
Stock Option (Right to Buy)
2022-10-03+100,000→ 100,000 totalExercise: $22.21Exp: 2032-10-02→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs") granted by the Issuer under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan") as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years: 25% of the RSUs will vest on each of the first, second, third and fourth anniversaries of the date of grant.
- [F2]The options were granted by the Issuer under the 2022 Inducement Plan as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.
- [F3]The options were granted by the Issuer under the 2022 Inducement Plan as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest as to 100% of the shares on the earlier of (a) FDA approval of a Zentalis product or (b) a Change in Control (as defined in the 2022 Inducement Plan).